Vircell Launches New Independent Molecular Control to Combat Monkeypox Outbreak

By LabMedica International staff writers
Posted on 31 Jul 2022

Image: Amplirun Monkeypox Virus DNA Control (Photo courtesy of Vircell)

Despite the fact that the first human cases of monkeypox were reported in 1970 in several African countries, it has not been until May 2022 when multiple cases of monkeypox were identified in different non-endemic countries, causing the current outbreak. By the time that the WHO (World Health Organization) declared the Moneypox a public health emergency of international concern in July 2022, Vircell (Granada, Spain) had already developed several solutions in order to help laboratories to detect this new menace. Vircell has now launched a new independent molecular control, Amplirun Monkeypox Virus DNA Control, which will help laboratories all over the world to combat the current outbreak.

Vircell is a leading provider of independent external run controls for nucleic acid testing with a long-term career in infectious disease diagnostics. During the COVID-19 pandemic, the company had developed SARS-COV-2 detection kits in record time, and it has now once again demonstrated its ability to adapt to changing laboratory needs with the newest solutions. Among Vircell’s solutions to detect monkeypox, the Amplirun Monkeypox Virus DNA Control stands out as a positive amplification control which contains purified DNA of Monkeypox virus to be used as a control research technique based on nucleic acids amplification. Some of the product’s outstanding features are:

Complete genome DNA control.
Any target can be amplified.
Allows validation of RTPCR assays.
Precise concentration in copies/µl.
Non-infectious materials with inactivation certificate.
Lyophilized presentation ensures stability and reduces transport costs. No special transportation conditions are required.
Independent third-party controls valid for any molecular testing platform

Amplirun Monkeypox Virus DNA Control could be used as: